Actively Recruiting
Open Trial of DAOIB to Treat Cognitive Impairment Caused by COVID-19
Led by Chang Gung Memorial Hospital · Updated on 2026-10-23
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of DAOIB in adults with cognitive impairments caused by long COVID. This open-label Phase 2 trial aims to study whether DAOIB can improve cognitive function, mood symptoms, overall functioning, and quality of life in these patients. The trial is sponsored by Chang Gung Memorial Hospital and targets individuals aged 18 to 100 years who meet specific health criteria. Participants will receive DAOIB for 24 weeks, with dosage adjustments every 8 weeks based on clinical evaluations. The study includes regular assessments at weeks 0, 8, 16, and 24 to monitor changes and effects. All patients receive the same treatment during the trial without a placebo group. During the study, participants undergo evaluations including the Alzheimers disease assessment scale for cognition, clinician interviews, activities of daily living scales, quality of life questionnaires, and mood and stress rating scales. These assessments occur at multiple time points to track progress. Safety and adherence are monitored throughout the 24-week period, with the main goal of measuring cognitive improvements and related outcomes.
CONDITIONS
Brief Title
DAOIB for the Treatment of Brain Fog
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here